BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21654544)

  • 1. The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms.
    Li X; Ni R; Chen J; Liu Z; Xiao M; Jiang F; Lu C
    Pancreas; 2011 Jul; 40(5):753-61. PubMed ID: 21654544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.
    Nagaraj S; Neumann J; Winzen B; Frank S; Ziske C; Sievers E; Koch N; Schmidt-Wolf IG
    Pancreas; 2008 Oct; 37(3):321-7. PubMed ID: 18815556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma.
    Nummer D; Suri-Payer E; Schmitz-Winnenthal H; Bonertz A; Galindo L; Antolovich D; Koch M; Büchler M; Weitz J; Schirrmacher V; Beckhove P
    J Natl Cancer Inst; 2007 Aug; 99(15):1188-99. PubMed ID: 17652277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer.
    Hoshi H; Sawada T; Uchida M; Saito H; Iijima H; Toda-Agetsuma M; Wada T; Yamazoe S; Tanaka H; Kimura K; Kakehashi A; Wei M; Hirakawa K; Wanibuchi H
    Int J Oncol; 2011 Mar; 38(3):619-27. PubMed ID: 21249315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
    Bockhorn M; Tsuzuki Y; Xu L; Frilling A; Broelsch CE; Fukumura D
    Clin Cancer Res; 2003 Sep; 9(11):4221-6. PubMed ID: 14519649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development.
    Zhang S; Hao J; Xie F; Hu X; Liu C; Tong J; Zhou J; Wu J; Shao C
    Carcinogenesis; 2011 Aug; 32(8):1183-9. PubMed ID: 21665894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uroguanylin inhibits proliferation of pancreatic cancer cells.
    Kloeters O; Friess H; Giese N; Buechler MW; Cetin Y; Kulaksiz H
    Scand J Gastroenterol; 2008; 43(4):447-55. PubMed ID: 18365910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects.
    Ugai S; Shimozato O; Yu L; Wang YQ; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2003 Oct; 10(10):771-8. PubMed ID: 14502230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of vascular endothelial growth factor C in pancreatic cancer and its effect upon lymph node metastasis].
    Li K; Li MJ; He T; Zheng Z; Zheng XL; Qu BH; Wang Y; Duan X; Zheng YJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2386-90. PubMed ID: 20137690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoted cancer growth by stimulating cell proliferation and decreasing apoptosis using a lentivirus-based EphB2 RNAi in pancreatic carcinoma CFPAC-1 cells.
    Hua YQ; Ouyang HQ; Chen Z; Meng ZQ; Luo JM; Lin JH; Zhou ZH; Chen H; Wang K; Liu LM
    Biomed Pharmacother; 2011 Mar; 65(2):123-31. PubMed ID: 21292437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts.
    Roland CL; Dineen SP; Toombs JE; Carbon JG; Smith CW; Brekken RA; Barnett CC
    Exp Biol Med (Maywood); 2010 Feb; 235(2):263-70. PubMed ID: 20404043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
    Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
    Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer.
    Wagner K; Schulz P; Scholz A; Wiedenmann B; Menrad A
    Clin Cancer Res; 2008 Aug; 14(15):4951-60. PubMed ID: 18676770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.